

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human NF2/Merlin in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human NF1 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 534428
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human NF2/Merlin Met363-Lys578 Accession # P35240
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

NF2 (Neurofibromin-2; also Merlin) is a 70-75 kDa tumor suppressor protein belonging to the ERM (ezrin, radixin, moesin) family of proteins. It participates in contact-mediated cell adhesion, thereby blocking cell proliferation and migration. Human NF2 is 595 amino acids (aa) in length. It contains three general regions. There is an N-terminal FERM domain (aa 1-302), an α -helical rod central region (aa 303-478), and a unique carboxy-terminal domain (aa 479-595). Confluence requires an absence of phosphorylation at Ser516 and Ser10. There are multiple potential splice variants. Four short forms less than 260 aa in length lack the aa range used for antigen immunization. There are at least eight additional isoforms that basically show an alternate start site coupled to an 11 aa substitution for aa 579-595. Lack of NF2 is associated with neurofibromatosis type II.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.